Tilburg, 20 November 2025 – Treeway, a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, today announced that results from its ASURE study have been accepted for a late-breaking oral communication at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference, the leading global meeting for Alzheimer’s disease research. The conference will take place in San Diego, California, from 1–4 December 2025.
Presentation Details
Event: 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
Location: San Diego, California, USA
Session: Late-Breaking Presentations
Date and Time: Thursday, 4 December 2025, 1:00 p.m. (Pacific Time)
The ASURE study is the first randomized, double-blind, placebo-controlled trial designed to evaluate the safety and pharmacokinetics of oral edaravone (TW001) in patients with mild-to-moderate Alzheimer’s disease (AD) over a 12-week treatment period.
The presentation will highlight key aspects of the study execution and summarize the primary and secondary outcomes from this Phase 2a trial, including safety, pharmacokinetics, oxidative stress, and exploratory endpoints.
Inez de Greef, PhD, CEO of Treeway, commented:
“We are pleased that the CTAD scientific committee recognizes the importance of investigating disease pathways such as oxidative stress. CTAD is the world’s leading forum for discussing clinical advances in Alzheimer’s disease, and we look forward to sharing the results of this study with colleagues, physicians, patients and the broader scientific community.”
The ASURE study provides important insights into oxidative stress biomarkers and safety as primary endpoints, as well as exploratory findings on cognition, EEG, and key molecular biomarkers.
About TW001
TW001 is Treeway’s proprietary oral formulation of edaravone and a potential disease-modifying therapy for Alzheimer’s disease. Alzheimer’s disease involves multiple pathological processes, including oxidative stress and neuroinflammation. Edaravone has been shown to reduce these processes and exhibits neuroprotective effects in preclinical AD models.
*The ASURE study is funded in part by the Alzheimer Drug Discovery Foundation (ADDF).
For more information, please contact:
Aster van Oordt
Communication Manager
info@treeway.nl
(+31) 135348272
